January 4, 2005 -- Following the lead of Wall Street, the Centient Biotech 200 lost 1.44%, dropping 51 points to 3495.16, which put it in between Nasdaq’s 2% loss and the NYSE Composite’s relatively small 1.25% decline. We look at the reasons behind StemCells’ meteoric rise, a collaboration for Targeted Genetics, and the anxiety surrounding American Pharma Partners, which faces an imminent FDA decision.
